ARTIDIS measures the physics of cancer to improve patient outcomes by ensuring each patient receives the right treatment, the first time. The company leverages cutting-edge mechanobiology technology to analyze the mechanical properties of tumors and their microenvironment, providing actionable insights for cancer research and clinical decision-making.
By measuring biomechanical forces within the tumor, ARTIDIS reveals metastatic potential and informs treatment choices in hours, preserving tissue integrity for standard pathology workflows. This approach adds a quantitative mechanical dimension to cancer analysis, complementing genomics, radiology, and traditional pathology.
The technology supports research into chemotherapy sequencing, targeted therapies, and checkpoint inhibitors by profiling cells in their native context — including stroma, immune cells, and physical barriers. ARTIDIS aims to transform cancer care through rapid, reproducible nanomechanical measurements that could guide therapy selection and improve patient outcomes.